Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Soiken HoldingsTSE:2385 -1.85%58 3-Year ROIIC % is 509.52 as of Jun. 2025, which is 249% above its 10-year median of 146.05. GuruFocus rates TSE:2385 with a GF Score™ of 58/100 and a GF Value™ of 円94.20 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,322 Biotechnology companies, Soiken Holdings ranks better than 91.15% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Soiken Holdings's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 509.52%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Soiken Holdings's 3-Year ROIIC % or its related term are showing as below:
TSE:2385's 3-Year ROIIC % is ranked better than 91.15% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs TSE:2385: 509.52
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Soiken Holdings 3-Year ROIIC % Related Terms
Soiken Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Soiken Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2385 vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Soiken Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soiken Holdings 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soiken Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Soiken Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Soiken Holdings (TSE:2385) has a 3-Year ROIIC % of 509.52 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Soiken Holdings and its competitors. This is 249% above median its historical median of 146.05. According to the industry distribution chart, Soiken Holdings ranks #117 out of 1322 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Soiken Holdings' 3-Year ROIIC % too high?
Soiken Holdings' current 3-Year ROIIC % of 509.52 is 249% above median its 10-year median of 146.05. Based on the distribution chart, Soiken Holdings ranks #117 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Soiken Holdings has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Soiken Holdings ranks #117 out of 1322 companies for 3-Year ROIIC %. This places Soiken Holdings in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Soiken Holdings and its competitors. Soiken Holdings's current 3-Year ROIIC % is 509.52, which is 249% above median its own 10-year median of 146.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円94.20, compared to a current price of 円212.00 — trading 125.1% above its estimated fair value. The current 3-Year ROIIC % is 509.52, which is 249% above median its 10-year median of 146.05. Soiken Holdings' overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current 3-Year ROIIC % is 509.52 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soiken Holdings (TSE:2385) Overvalued in 2026?
Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued.
The current stock price of 円212.00 is trading 125.1% above its estimated GF Value™ of 円94.20.
GuruFocus considers Soiken Holdings to be Significantly Overvalued.
Key valuation signals for TSE:2385:
3-Year ROIIC %: 509.52 (249% above median its 10-year median of 146.05)
GF Value™: 円94.20 vs. price of 円212.00 (125.1% above fair value)
No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
58GF Score
Get the complete analysis for TSE:2385
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2385 has been successfully added to your 
